IN THE CLAIMS:

Please rewrite the pending claims as follows:

1. (Currently Amended) A compound of the formula:

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof, wherein:

one of X and Y is C=O and the other is CH2 or C=O;

 R^1 is H, (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heterocycloalkyl, (C_0-C_8) alkyl- (C_0) 0R 3 , (C_0) 0R 3 , (C_0) 0R 3 , (C_0-C_8) alkyl- (C_0) 0R 3 , (C_0) 0R 3 , (C_0) 0R 3 R 3 0 or (C_0-C_8) alkyl- (C_0) 0R 5 ;

 R^2 is H, F, benzyl, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl, with the proviso that when n is 0, R^2 is H or (C_1-C_6) alkyl;

 R^3 and $R^{3'}$ are independently (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, (C_0-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- $O(C_3-C_8)$ alkyl

 R^4 is (C_1-C_8) alkyl, (C_2-C_8) alkynyl, (C_1-C_4) alkyl- OR^5 , benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, or (C_0-C_4) alkyl- (C_2-C_5) heteroaryl;

 R^5 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl;

9516-048-999

· -2 -

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-R^5$ or the R^6 groups can join to form a heterocycloalkyl group;

n is 0 or 1; and the * represents a chiral-carbon center, with the proviso that when n is 0 then R¹ is not H.

- 2. (Original) The compound of claim 1, wherein the compound is the Renantiomer or substantially R.
- 3. (Original) The compound of claim 1, wherein the compound is the Senantiomer or substantially S.
- 4. (Original) The compound of claim 1, wherein the compound is a recentic mixture.
- 5. (Original) The compound of claim 1, wherein the enantiomeric excess is about 90% ee or more.
 - 6. (Original) A compound of claim 1, wherein R² is H or (C₁-C₄)alkyl.
- 7. (Original) A compound of claim 1, wherein R¹ is H, (C₁-C₄)alkyl, CH₂OCH₃, CH₂CCH₂OCH₃, or

wherein Q is O or S, and each occurrence of R^7 is independently H₁(C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, halogen, (C₀-C₄)alkyl-(C₁-C₅)heteroaryl, (C₀-C₈)alkyl-N(R^6)₁, (C₁-C₈)alkyl-O(C₂-C₅)heteroaryl, (C₀-C₈)alkyl-N(R^6)₁, (C₁-C₈)alkyl-O(CO) R^5 , or C(O)O R^5 , or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

NY3 -1415999.1

- 8. (Original) A compound of claim 1, wherein R¹ is C(O)R³.
- 9. (Original) A compound of claim 1, wherein R¹ is C(O)OR⁴.
- 10. (Currently Amended) The A compound of formula! having the formula:

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof, wherein:

 R^1 is H, (C₁–C₈)alkyl, (C₃–C₇)cycloalkyl, (C₂–C₈)alkenyl, (C₂–C₈)alkynyl, benzyl, aryl, (C₀–C₄)alkyl–(C₁–C₆)heterocycloalkyl, (C₀–C₄)alkyl–(C₂–C₅)heteroaryl, C(O)R³, C(S)R³, C(O)OR⁴, (C₁–C₈)alkyl–N(R⁶)₂, (C₁–C₈)alkyl–OR⁵, (C₁–C₈)alkyl–C(O)OR⁵, C(O)NHR³, C(S)NHR³, C(O)NR³R³, C(S)NR³R³ or (C₁–C₈)alkyl–O(CO)R⁵;

R² is H or (C₁-C₈)alkyl;

 R^3 and $R^{3'}$ are independently (C₁–C₈)alkyl, (C₃–C₇)cycloalkyl, (C₂–C₈)alkenyl, (C₂–C₈)alkynyl, benzyl, aryl, (C₀–C₄)alkyl–(C₁–C₅)heterocycloalkyl, (C₀–C₄)alkyl–(C₂–C₅)heteroaryl, (C₀–C₈)alkyl–N(R^6)₂, (C₁–C₈)alkyl–OR⁵, (C₁–C₈)alkyl–O(O)R⁵, or C(O)OR⁵;

 R^4 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, (C_1-C_4) alkyl- (C_1-C_5) heterocycloalkyl, or (C_0-C_4) alkyl- (C_2-C_5) heterocycloalkyl, or (C_0-C_4) alkyl- (C_0-C_5) heterocycloalkyl, or (C_0-C_5) heterocycloalk

 R^5 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl;

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and

9516-048-999

4-

the * represents a chiral-carbon center.

11. (Original) A compound of claim 10, wherein R¹ is H, (C₁-C₄)alkyl, CH₂OCH₃, CH₂CCH₃, or

$$\sim$$
 CH₂ , \sim CH₂ \sim OI \sim CH \sim R⁷ \sim R⁷ \sim R⁷ ,

wherein Q is O or S, and each occurrence of R^7 is independently H₁(C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, halogen, (C₀-C₄)alkyl-(C₁-C₆)heterocycloalkyl, (C₀-C₄)alkyl-(C₂-C₅)heteroaryl, (C₀-C₈)alkyl-N(R^6)₂, (C₁-C₈)alkyl-O(CO) R^5 , (C₁-C₈)alkyl-O(CO) R^5 , or C(O)OR⁵, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

- 12. (Original) A compound of claim 10, wherein R¹ is C(O)R³.
- 13. (Original) A compound of claim 10, wherein R¹ is C(O)OR⁴.
- 14. (Currently Amended) The A compound of claim 1 having the formula:

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, disstereomer, recemete, or mixture of stereoisomers thereof, wherein:

 R^1 is H, (C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, (C₀-C₄)alkyl-(C₁-C₆)heterocycloalkyl, (C₀-C₄)alkyl-(C₂-C₅)heteroaryl, C(0) R^3 , C(S) R^3 ,

NY2 -1415999.1

C(O)OR⁴, (C₁-C₈)alkyl-N(R⁶)₂, (C₁-C₈)alkyl-OR⁵, (C₁-C₈)alkyl-C(O)OR⁵, C(O)NHR³, C(S)NHR³, C(O)NR³R³ or (C₁-C₈)alkyl-O(CO)R⁵;

 \mathbb{R}^2 is H or (C_1-C_8) alkyl;

 R^3 and R^3 are independently (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, (C_0-C_8) alkyl- (C_1-C_8) alkyl- $(C_$

 R^4 is (C_1-C_8) alkyi, (C_2-C_8) alkenyi, (C_2-C_8) alkynyi, (C_1-C_4) alkyi- OR^5 , benzyi, aryi, (C_0-C_4) alkyi- (C_1-C_6) heterocycloalkyi, or (C_0-C_4) alkyi- (C_2-C_5) heteroaryi;

 R^5 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl;

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_4) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and

the * represents a chiral-carbon center.

15. (Original) A compound of claim 14, wherein R¹ is H, (C₁-C₄)alkyl, CH₂OCH₃, CH₂CH₂OCH₃, or

$$m_{CH_2}$$
, m_{CH_2} or m_{CH} m_{R^7} ,

wherein Q is O or S, and each occurrence of R^7 is independently H,(C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, halogen, (C₉-C₄)alkyl-(C₁-C₆)heterocycloalkyl, (C₉-C₄)alkyl-(C₂-C₅)heteroaryl, (C₉-C₈)alkyl-N(R^6)₂, (C₁-C₈)alkyl-OR⁵, (C₁-C₈)alkyl-O(CO) R^5 , or C(O)OR⁵, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

- 16. (Original) A compound of claim 14, wherein R1 is C(O)R3.
- 17. (Original) A compound of claim 14, wherein R¹ is C(O)OR⁴.

 9516-048-999

 -6 NY2-1415999.1

18. (Currently Amended) A compound of claim-1 having the formula:

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof, wherein:

 R^2 is H, (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, (C_1-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- OR^5 , (C_1-C_8) alkyl- $C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^3$, $C(S)NR^3R^3$ or (C_1-C_8) alkyl- $O(CO)R^5$;

R² is H or (C₁-C₈)alkyl;

 R^3 and R^3 are independently (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkylyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_8) heteroaryl, (C_0-C_8) alkyl- (C_1-C_8) alkyl- $(C_$

 R^4 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, (C_1-C_4) alkyl- OR^5 , benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, or (C_0-C_4) alkyl- (C_2-C_5) heteroaryl;

R⁵ is (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, or (C₂-C₅)heteroaryl;

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and

the * represents a chiral-carbon center.

9516-048-999 -7 - 1415999.1

19. (Original) A compound of claim 18, wherein R¹ is H, (C₁-C₄)alkyl, CH₂OCH₃, CH₂CCH₂OCH₃ or

$$\cdots$$
CH₂ , \cdots CH₂ or \cdots CH₂ $\stackrel{R^7}{\sim}$ $\stackrel{R^7}{\sim$

wherein Q is O or S, and each occurrence of R^7 is independently H,(C_1 - C_8)alkyl, (C_3 - C_7)cycloalkyl, (C_2 - C_8)alkenyl, (C_2 - C_8)alkynyl, benzyl, aryl, halogen, (C_0 - C_4)alkyl-(C_1 - C_6)heterocycloalkyl, (C_0 - C_4)alkyl-(C_2 - C_5)heteroaryl, (C_0 - C_8)alkyl-N(R^6)₂, (C_1 - C_8)alkyl-OR⁵, (C_1 - C_8)alkyl-O(O)R⁵, or C(O)OR⁵, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

- 20. (Original) A compound of claim 18, wherein R¹ is C(O)R³.
- 21. (Original) A compound of claim 18, wherein R¹ is C(O)OR⁴.
- 22. (Currently Amended) A compound of claim 1 having the formula:

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof, wherein:

 $R^{1} \text{ is H, } (C_{1}-C_{6}) \text{alkyl, } (C_{3}-C_{7}) \text{cycloalkyl, } (C_{2}-C_{8}) \text{alkenyl, } (C_{2}-C_{8}) \text{alkynyl, benzyl, aryl, } (C_{0}-C_{4}) \text{alkyl-} (C_{1}-C_{6}) \text{heterocycloalkyl, } (C_{0}-C_{4}) \text{alkyl-} (C_{2}-C_{5}) \text{heteroaryl, } C(O)R^{3}, C(S)R^{3}, C(O)OR^{4}, (C_{1}-C_{8}) \text{alkyl-} OR^{5}, (C_{1}-C_{8}) \text{alkyl-} C(O)OR^{5}, C(O)NHR^{3}, C(S)NHR^{3}, C(O)NR^{3}R^{3'}, C(S)NR^{3}R^{3'} \text{ or } (C_{1}-C_{8}) \text{alkyl-} O(CO)R^{5};$

9516-048-999

-8 -

NY3 -1415999.L

R2 is H or (C1-C4)alkyl;

 R^3 and $R^{3'}$ are independently (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, (C_0-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- $O(C_3)$ alkyl- $O(C_3)$ or $C(O)OR^5$, (C_1-C_8) alkyl- $O(CO)R^5$, or $C(O)OR^5$;

 R^4 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, (C_1-C_4) alkyl- (C_1-C_6) heterocycloalkyl, or (C_0-C_4) alkyl- (C_2-C_5) heteroaryl;

 R^5 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl;

each occurrence of \mathbb{R}^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-\mathbb{R}^5$ or the \mathbb{R}^6 groups can join to form a heterocycloalkyl group; and

the * represents a chiral-carbon center.

23. (Original) A compound of claim 22, wherein R¹ is (C₁-C₆)alkyl, benzyl, CH₂OCH₃, CH₂OCH₃, or

$$m_{CH_2}$$
, m_{CH_2} or m_{CH} q^7 ,

wherein Q is O or S, and each occurrence of R^7 is independently H,(C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, halogen, (C₀-C₄)alkyl-(C₁-C₆)heterocycloalkyl, (C₀-C₄)alkyl-(C₂-C₅)heteroaryl, (C₀-C₈)alkyl-N(R^6)₂, (C₁-C₈)alkyl-O(CO) R^5 , or C(O)O R^5 , or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

- 24. (Original) A compound of claim 22, wherein R¹ is C(O)R³.
- 25. (Original) A compound of claim 24, wherein R^3 is (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, (C_1-C_8) alkyl, aryl, or (C_0-C_4) alkyl- (C_3-C_4) alkyl- (C_3-C_4)

9516-048-999

-9 -

26. (Original) A compound of claim 25, wherein heteroaryl is pyridyl, furyl, or thienyl.

- 27. (Original) A compound of claim 22, wherein R¹ is C(O)OR⁴.
- 28. (Currently Amended) A compound of claim 1 having the formula:

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof, wherein:

 R^1 is H, (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, (C_1-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- OR^5 , (C_1-C_8) alkyl- $C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^3$, $C(S)NR^3R^3$ or (C_1-C_8) alkyl- $O(CO)R^5$;

R² is H or (C₁-C₄)alkyl;

 R^3 and R^3 'are independently (C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, (C₀-C₄)alkyl-(C₁-C₆)heterocycloalkyl, (C₀-C₄)alkyl-(C₂-C₅)heteroaryl, (C₀-C₈)alkyl-N(R^6)₂, (C₁-C₈)alkyl-O R^5 , (C₁-C₈)alkyl-O(O) R^5 , or C(O)O R^5 ;

 R^4 is (C_1-C_8) alkyl, (C_2-C_8) alkynyl, (C_1-C_4) alkyl-OR⁵, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_5) heterocycloalkyl, or (C_0-C_4) alkyl- (C_2-C_5) heterocycloalkyl- (C_0-C_4) alkyl- (C_0-C_5) heterocycloalkyl- (C_0-C_5) heterocyclo

 R^5 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl;

9516-048-999

-10 -

each occurrence of \mathbb{R}^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-\mathbb{R}^5$ or the \mathbb{R}^6 groups can join to form a heterocycl alkyl group; and

the * represents a chiral-carbon center.

29. (Original) A compound of claim 28, wherein R¹ is (C₁-C₄)alkyl, benzyl, CH₂OCH₃, CH₂CCH₂OCH₃, or

$$m_{CH_2}$$
, m_{CH_2} or m_{R^7} q^7 ,

wherein Q is O or S, and each occurrence of R^7 is independently H,(C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, halogen, (C₀-C₄)alkyl-(C₁-C₆)heterocycloalkyl, (C₀-C₄)alkyl-(C₂-C₅)heteroaryl, (C₀-C₈)alkyl-N(R^6)₂, (C₁-C₈)alkyl-OR⁵, (C₁-C₈)alkyl-O(CO) R^5 , or C(O)OR⁵, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

- 30. (Original) A compound of claim 28, wherein R¹ is C(O)R³.
- 31. (Original) A compound of claim 30, wherein \mathbb{R}^3 is (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, (C_1-C_4) alkyl, aryl, or (C_0-C_4) alkyl- \mathbb{OR}^5 .
- 32. (Original) A compound of claim 31, wherein heteroaryl is pyridyl, furyl, or thienyl.
 - 33. (Original) A compound of claim 28, wherein R¹ is C(O)OR⁴.
 - 34. (Currently Amended) A compound of claim 1 having the formula:

9516-048-999

-11 -

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof, wherein:

 R^1 is H, (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, (C_1-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- OR^5 , (C_1-C_8) alkyl- $C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(S)NR^3R^3$ or (C_1-C_8) alkyl- $O(CO)R^5$;

 R^3 and R^3 are independently (C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, (C₀-C₄)alkyl-(C₁-C₆)heterocycloalkyl, (C₀-C₄)alkyl-(C₂-C₅)heteroaryl, (C₀-C₈)alkyl-N(R^6)₂, (C₁-C₈)alkyl-O R^5 , (C₁-C₈)alkyl-O(O) R^5 , or C(O)O R^5 ;

 R^4 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, (C_1-C_4) alkyl- (C_1-C_6) heterocycloalkyl, or (C_0-C_4) alkyl- (C_2-C_5) heterocycloalkyl, or (C_0-C_4) alkyl- (C_0-C_5) heterocycloalkyl, or (C_0-C_4) alkyl- (C_0-C_5) heterocycloalkyl

 R^5 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl;

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- (C_0) or the R^6 groups can join to form a heterocycloalkyl group; and

the * represents a chiral-carbon center.

35. (Original) A compound of claim 34, wherein R¹ is (C₁-C₆)alkyl, benzyl, CH₂OCH₃, CH₂CCH₃, or

MY2-1415999.1

$$\sim CH_2$$
 or $\sim CH_2$ $\sim CH_2$ $\sim CH_2$ $\sim CH_2$ $\sim CH_2$

wherein Q is O or S, and each occurrence of \mathbb{R}^7 is independently $H_1(C_1-C_1)$ alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkynyl, benzyl, aryl, halogen, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, (C_0-C_8) alkyl- $N(\mathbb{R}^6)_2$, (C_1-C_8) alkyl- (C_1-C_8) alkyl- (C_1-C_8) alkyl- (C_1-C_8) alkyl- (C_1-C_8) alkyl- (C_1-C_8) or (C_1-C_8) alkyl- (C_1-C_8) alkyl-

- 36. (Original) A compound of claim 34, wherein R¹ is C(O)R³.
- 37. (Original) A compound of claim 36, wherein R³ is (C₀-C₄)alkyl-(C₂-C₅)heteroaryi, (C₁-C₅)alkyl, aryl, or (C₀-C₄)alkyl-OR⁵.
- 38. (Original) A compound of claim 37, wherein heteroaryl is pyridyl, furyl, or thienyl.
 - 39. (Original) A compound of claim 34, wherein R¹ is C(O)OR⁴.
 - 40. (Currently Amended) A compound of claim 1 having the formula:
 - I-1 (2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-ylmethyl)-carbamic acid *tert*-butyl ester;
 - I-2 4-(aminomethyl)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione;
 - I-3 N-(2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl)-acetamide;
 - I-4 N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl)methyl} cyclopropyl-carboxamide;
 - I-5 (2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-ylmethyl)-carbamic acid ethyl ester;
 - I-6 2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-ylmethyl)-carbamic acid benzyl ester;

9516-048-999

-13 -

- I-7 2-chloro-N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}acetamide;
- I-8 2-(dimethylamino)-N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}-acetamide;
- I-9 1-tert-butyl-3-(2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-ylmethyl)-urea;
- I-10 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}-3,3-dimethylbutanamide;
- I-11 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)-3-pyridylcarboxamide;
- I-12 3-{1-oxo-4-(benzylamino)lsoindolin-2-yl}piperidine-2,6-dione;
- I-13 2-(2,6-dioxo(3-piperidyl))-4-(benzylamino)isoindolino-1,3-dione;
- I-14 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)msthyl}propanamide;
- I-15 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}-3-pyridylcarboxamide;
- I-16 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}heptanamide;
- I-17 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}-2-furylearboxamide;
- I-18 2-azido-N-(2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl-methyl)-acetamide;
- I-19 2-amino-N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}acetamide;
- I-20 ethyl 6-(N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}carbamoyl)hexanoate;

NY2 -1415999.1

- I-21 3-((tert-butoxy)carbonylamino)-N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl}methyl}propanamide;
- I-22 3-amino-N-{(2-(2,6-di xo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}propanamide;
- I-23 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}-2-thienylcarboxamide;
- I-24 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}-2-methoxyacetamide;
- I-25 (N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}carbamoyl)methyl acetate;
- I-26 ethyl 2-((N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}carbamoyl) amino)acetate;
- I-27 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)methyl}(ethylsmino)carboxamide;
- I-28 2-(2,6-Dioxo(3-piperidyl))-4-[(2-furylmethyl)amino]isoindoline-1,3-dione
- I-29 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)-2-methoxyacetamide;
- I-30 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)heptanamide;
- I-31 {N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)carbamoyl}methyl acetate;
- I-32 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)pentanamide;
- I-33 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)-2-thienylcarboxamide;
- I-34 methyl {N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)carbamoyl} formate;
- I-35 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)-2-furylcarboxamide;

9516-048-999 -I5 - ^{NY2-1415999,1}

- I-36 N-(2-(2,6-dioxo(3-piperidyl))-1,3-diox isoindolin-4-yl)benzamide;
- I-37 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)propanamide;
- I-38 methyl 3-{N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)carbamoyl}propanoate;
- I-39 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)-2-phenylacetamide;
- I-40 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)-2-pyridylcarboxamide;
- I-41 N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)-2-chloroacetamide;
- I-42 2-azido-N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)acetamide;
- I-43 2-amino-N-(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl)acetamide;
- I-44 N-(2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl)-2-chloroacetamide;
- I-45 2-azido-N-(2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl)acetamide;
- I-46 2-amino-N-(2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl)acetamide;
- I-47 3-{4-((2-furylmethyl)amino)-1-oxoisoindolin-2-yl}piperidine-2,6-dione; or
- I-48 3-(1-oxo-4-(pentylamino)isoindolin-2-yl)piperidine-2,6-dione;
- I-49 2-(2,6-dioxo-piperidin-3-yl)-4-(2-methoxy-ethylamino)-isoindole-1,3-dione;
- I-50 2-benzyloxy-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide;
- I-51 2-(2,6-dioxo-piperidin-3-yl)-4-pentylamino-isoindole-1,3-dione;
- I-52 3-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-benzamide;
- I-53 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-phenoxy-acetamide;

NY2-1415999.1

- I-54 4-(2-benzyloxy-ethylamino)-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione;
- I-55 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-benzamide;
- I-56 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3-methyl-benzamide;
- I-57 N-[2-(2,6-dioxo-piperidin-3-yI)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3-methoxy-benzamide;
- I-58 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3-trifluoromethyl-benzamide;
- I-59 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1*H*-isoindol-4-yl]-3-nitro-benzamide;
- I-60 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-butyramide;
- I-61 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-methylamino-acetamide;
- I-62 2-(2,6-dioxo-piperidin-3-yl)-4-heptylamino-isoindole-1,3-dione;
- I-63 4-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-benzamide;
- I-64 cyclopropanecarboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-amide;
- I-65 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4-fluoro-benzamide;
- I-66 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4-trifluoromethyl-benzamide;
- I-67 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4-methyl-benzamide;

9516-048-999 -17 -

- I-68 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4-nitro-benzamide;
- I-69 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-ethoxy-acetamide;
- I-70 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-methylsulfanyl-acetamide;
- I-71 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-methoxy-benzamide;
- I-72 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-fluoro-benzamide;
- I-73 7-amino-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}heptanamide;
- I-74 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}butanamide;
- I-75 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}benzamide;
- I-76 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl}phenylacetamide;
- I-77 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-pyridylcarboxamide;
- I-78 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl} undecamide;
- I-79 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-methylpropanamide;
- I-80 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl}cyclopentylcarboxamide;
- I-81 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl}cyclohexylcarboxamide;

9516-048-999 -18 -

- I-82 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl} (phenylamino)carboxamide;
- I-83 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl}(butylamino)carboxamide;
- I-84 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl} (propylamino)carboxamide;
- I-85 N-{(2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl} (cyclohexylamino)carboxamide;
- I-86 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl}[(methylethylamino)]carboxamide;
- I-87 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl}(octylamino)carboxamide;
- I-88 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl} (benzylamino)carboxamide;
- I-89 N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl] methyl}(cyclopropylamino)carboxamide;
- I-90 2-chloro-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-benzamide;
- I-91 [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]carbamic acid benzyl ester;
- I-92 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide;
- I-93 Pentanoic acid [2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-amide;
- I-94 N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-propionamide;

9516-048-999

-19 -

- I-95 N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-nicotinamide;
- I-96 2-(2,6-dioxo-piperidin-3-yl)-4-{[(furan-2-ylmethyl)-amino]-methyl}-isoindole-1,3-dione;
- I-97 N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-benzamide;
- I-98 2-dimethylamino-N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide;
- I-99 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-methyl-benzamide;
- I-100 Heptanoic acid[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-dihydro-1H-isoindol-4-yl]-amide;
- I-101 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3,3-dimethyl-butyramide;
- I-102 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-isobutyramide;
- I-103 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3-phenyl-propionamide;
- I-104 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4-methoxy-benzamide
- I-105 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-trifluoromethyl-benzamids;
- I-106 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-malonamic acid methyl ester;
- I-107 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-3-methoxy-propionamide;

9516-048-999

-20 -

- I-108 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-2-hydroxy-acetamide
- I-109 4-[(furan-2-ylmethyl)-amin]-2-(1-methyl-2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione;
- I-110 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-isonicotinamide;
- I-111 N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide;
- I-112 {5-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylcarbamoyl]-pentyl}-carbamic acid benzyl ester;
- I-113 2-(2,6-Dioxo(3-piperidyl))-4-({[(cyclohexylamino)thioxomethyl]amino} methyl)isoindole-1,3-dione;
- I-114 2-(2,6-Dioxo(3-piperidyl))-4-({[(ethylamino)thioxomethyl]amino} methyl)isoindole-1,3-dione;
- I-115 2-(2,6-Dioxo(3-piperidyl))-4-({[(propylamino)thioxomethyl]amino} methyl)isoindole-1,3-dione;
- I-116 N-[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]-2-chlorobenzylamine;
- I-117 {5-[2-(2,6-Dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylcarbamoyl]-pentyl}-carbamic acid benzyl ester;
- I-118 2-Methoxy-N-[2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-acetamide;
- I-119 Pentanoic acid [2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydrolH-isoindol-4-yl]-amide;
- I-120 Heptanoic acid [2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-amide;

9516-048-999 -21 - NY7-1419999.1

- I-121 3-Chloro-N-[2-(3-methyl-2,6-di xo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-benzamide;
- I-122 N-[2-(3-Methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-propionsmide;
- I-123 Thiophene-2-carboxylic acid [2-(3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-amide;
- I-124 2-(2,6-Dioxo-piperidin-3-yl)-4-[(5-methyl-furan-2-ylmethyl)-amino]-isoindole-1,3-dione;
- I-125 2-(2,6-Dioxo-piperidin-3-yl)-4-[(5-hydroxymethyl-furan-2-ylmethyl)-amino]-isoindole-1,3-dione;
- I-126 2-(2,6-Dioxo-piperidin-3-yl)-4-[(thiophen-2-ylmethyl)-amino]-isoindole-1,3-dione;
- I-127 4-(3-Chloro-benzylamino)-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione;
- I-128 2-(2,6-Dioxo-piperidin-3-yl)-4-[(pyridin-3-ylmethyl)-amino]-isoindole-1,3-dione;
- I-129 5-{[2-(2,6-Dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylamino]-methyl}-furan-2-carboxylic acid;
- I-130 4-[(4,5-Dimethyl-furan-2-ylmethyl)-amino]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione;
- I-131 4-[(Benzofuran-2-ylmethyl)-amino]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione;
- I-132 4-(3-Chloro-benzylamino)-2-(3-methyl-2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione;
- I-133 3-[4-(3-Chloro-benzylamino)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione;

NY2 -1415999.1

9516-048-999

-22 -

- I-134 N-{[2-(2,6-Dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(cyclopentylamino)carboxamide;
- I-135 N-{(2-(2,6-Dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(3-pyridylamino)carboxamide Hydrochloride;
- I-136 N-{[2,(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}piperidylcarboxamide;
- I-137 Tert-Butyl 4-(N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(carbamoyl)piperazinecarboxylate;
- I-138 N-{[2-(2,6-Dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-y1]methyl}(diethylamino)carboxamide;
- I-139 Cyclopropyl-N-{[2-(3-methyl-2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}carboxamide;
- I-140 N-{[2-(2,6-Dioxo(3-piperidyl))-1-oxoisoindolin-4yl}methyl}cyclopropylcarboxamide;
- I-141 N-{[2-(2,6-Dioxo(3-piperidyl))-1-oxoisoindolin-4-yl]methyl}(ethylamino)carboxamide; or
- I-142 Piperazine-I-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastercomer, racemate, or mixture of stereoisomers thereof.

- 41. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim I and a pharmaceutically acceptable vehicle or carrier.
- 42. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 10 and a pharmaceutically acceptable vehicle or carrier.

NY3 -1415999.1

9516-048-999

-23 -

- 43. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 14 and a pharmaceutically acceptable vehicle or carrier.
- 44. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 18 and a pharmaceutically acceptable vehicle or carrier.
- 45. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 22 and a pharmaceutically acceptable vehicle or carrier.
- 46. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 28 and a pharmaceutically acceptable vehicle or carrier.
- 47. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 34 and a pharmaceutically acceptable vehicle or carrier.
- 48. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 40 and a pharmaceutically acceptable vehicle or carrier.
- 49. (Original) A method of modulating the production of TNF-c in a mammal comprising administering to said mammal an effective amount of a compound of claim 1.
- 50. (Currently Amended) A method of modulating the production of IL-1 β in a mammal comprising administering to said mammal an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastersomer, racemate, or mixture of stereoisomers thereof, wherein;

one of X and Y is O=O and the other is CH₂ or C=O;

R¹ is H. (C₁-C₈)alkyl. (C₂-C₇)cycloalkyl. (C₂-C₈)alkenyl. (C₂-C₈)alkynyl. benzyl. aryl. (C₀-C₄)alkyl-(C₁-C₈)beteroaryl. C(O)R³. C(S)R³.

C(O)OR⁴. (C₁-C₈)alkyl-N(R⁶). (C₁-C₈)alkyl-OR⁵. (C₁-C₈)alkyl-C(O)OR³. C(O)NHR³.

C(S)NHR³. C(O)NR³R³. C(S)NR³R³. or (C₁-C₈)alkyl-O(CO)R⁵.

R² is H, F, benzyl, (C₁-C₈)alkyl, (C₂-C₈)alkenyl, or (C₂-C₈)alkynyl;

R³ and R³ are independently (C₁-C₈)alkyl, (C₂-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkyl, (C₂-C₈)alkyl, (C₂-C₄)alkyl-(C₂-C₅)heterocycloalkyl, (C₂-C₄)alkyl-(C₂-C₅)heterocycloalkyl, (C₂-C₄)alkyl-N(R⁶)₂, (C₁-C₈)alkyl-OR⁵, (C₁-C₈)alkyl-C(O)OR⁵, (C₁-C₈)alkyl-O(CO)R⁵, or C(O)OR⁵;

R⁴ is (C₁-C₄)alkyl. (C₂-C₄)alkenyl. (C₂-C₄)alkyl-OR³. benzyl. arvl. (C₀-C₄)alkyl-(C₁-C₄)beteroscyl. arvl. (C₀-C₄)alkyl-(C₂-C₄)beteroscyl.

R⁵ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, benzyl, aryl, or (C₂-C₅)heteroaryl;

each occurrence of R⁶ is independently H. (C₁-C₅)alkyl. (C₂-C₅)alkynyl. benzyl. aryl. (C₂-C₅)heteroaryl. or (C₀-C₅)alkyl-C(O)O-R⁵ or the R⁶ groups can join to form a heterocycloalkyl group;

n is 0 or 1; and the * represents a chiral-carbon center; with the provise that when n is 0 then R¹ is not H.

NY2 -1415999.1

51. (Currently Amended) A method of modulating the production of IL-10 in a mammal comprising administering to said mammal an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, recemate, or mixture of stereoisomers thereof, wherein:

one of X and Y is C=O and the other is CH2 or C=O:

R¹ is H. (C₁-C₈)alkyl. (C₂-C₇)cycloalkyl. (C₂-C₈)alkenyl. (C₂-C₈)alkynyl. benzyl. aryl. (C₂-C₄)alkyl-(C₁-C₅)beterocycloalkyl. (C₂-C₄)alkyl-(C₂-C₅)beterocycloalkyl. (C₃-C₄)alkyl-(C₂-C₅)beterocycloalkyl. C(S)R³. C(S)R³. C(O)OR⁴. (C₁-C₈)alkyl-OR⁵. (C₁-C₈)alkyl-C(O)OR⁵. C(O)NHR³. C(S)NHR³. C(S)NHR³. C(S)NR³R³ or (C₁-C₈)alkyl-O(CO)R⁵.

R² is H. F. benzyl. (C₁-C₂)alkyl. (C₂-C₃)alkenyl. or (C₂-C₃)alkynyl:

R³ and R³ are independently (C₁-C₂)alkyl. (C₂-C₇)cycloalkyl. (C₂-C₃)alkenyl. (C₂-C₄)alkyl. (C₂-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₃)alkyl. (C₁-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₄)alkyl. (C₁-C₃)alkyl. (C₁-C₄)alkyl. (C₁-C₄

R⁴ is (C₁-C₄)alkvi. (C₂-C₄)alkvnyi. (C₁-C₄)alkvi-OR⁵, benzyi. arvi. (C₀-C₄)alkvi-(C₁-C₄)beterocycloalkvi. or (C₀-C₄)alkvi-(C₂-C₄)beteroarvi:

R⁵ is (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, or (C₂-C₃)heteroaryl;

each occurrence of R⁶ is independently H. (C₁-C₆)alkyl. (C₂-C₈)alkynyl. (C₂-C₈)alkynyl. benzyl. aryl. (C₂-C₅)heteroaryl. or (C₀-C₈)alkyl-C(O)O-R⁵ or the R⁶ groups can join to form a heterocycloalkyl group.

9516-048-999

-26 -

n is 0 or 1; and the * represents a chiral-carbon center; with the proviso that when n is 0 then R^1 is not H.

52. (Currently Amended) A method of modulating the production or proliferation of T-cells in a mammal comprising administering to said mammal an effective amount of a compound of the formula:

or a pharmaceutically acceptable sait, hydrate, solvate, clathrate, enantiomer, disatereomer, racemate, or mixture of stereoisomers thereof, wherein:

one of X and Y is C=O and the other is CH2 or C=O;

R¹ is H. (C₁-C₈)alkyl. (C₂-C₂)cycloalkyl. (C₂-C₈)alkenyl. (C₂-C₈)alkynyl. benzyl. aryl. (C₀-C₄)alkyl-(C₁-C₅)heteroaryl. C(O)R³. C(S)R³.

C(O)OR⁴. (C₁-C₈)alkyl-N(R⁶)₂. (C₁-C₈)alkyl-OR⁵. (C₁-C₈)alkyl-C(O)OR⁵. C(O)NHR³.

C(S)NHR³. C(O)NR³R³. C(S)NR³R³ or (C₁-C₈)alkyl-O(CO)R⁵.

R² is H. F. benzyl (C₁-C₂)alkyl (C₂-C₃)alkenyl or (C₂-C₃)alkynyl;

R³ and R^{3'} are independently (C₁C₈)alkyl. (C₂-C₇)cycloalkyl. (C₂-C₈)alkenyl. (C₂-C₈)alkyl. (C₁-C₆)heterocycloalkyl. (C₁-C₆)alkyl-(C₂-C₇)heteroaryl. (C₁-C₈)alkyl-N(R⁵)₂. (C₁-C₈)alkyl-OR⁵. (C₁-C₈)alkyl-O(O)R⁵. (C₁-C₈)alkyl-O(O)R⁵.

R⁴ is (C₁-C₈)alkyl, (C₂-C₈)alkynyl, (C₁-C₈)alkyl-OR⁵, benzyl, aryl, (C₁-C₄)alkyl-(C₁-C₄)heterogycloalkyl, or (C₁-C₄)alkyl-(C₂-C₄)heterogycloalkyl,

R⁵ is (C₁-C₂)alkyl. (C₂-C₂)alkenyl. (C₂-C₃)alkynyl. benzyl. arvl. or (C₂-C₃)heteroaryl;

NY2-1415999.1

each occurrence of R⁶ is independently H. (C₁-C₂)alkyl. (C₂-C₃)alkenyl. (C₂-C₃)alkynyl. benzyl. aryl. (C₂-C₃)heteroaryl. or (C₁-C₃)alkyl-C(O)O-R⁵ or the R⁶ groups can join to form a heterocycloalkyl group;

n is 0 or 1; and the * represents a chiral-carbon center; with the proviso that when n is 0 then R¹ is not H.

- 53. (Original) A method of treating cancer in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1, 10, 14, 18, 22, 28, 34, or 40.
- 54. (Original) The method of claim 53, wherein the cancer is a solid tumor or a blood born tumor.
- 55. (Original) The method of claim 53, wherein the cancer is cancer of the skin, blood, lymph node, breast, cervix, uterus, gastrointestinal tract, lung, ovary, prostate, mouth, brain, head, neck, throat, colon, rectum, testes, kidney, pancreas, bone, spleen, liver, bladder, larynx, or nasal passages.
- 56. (Original) The method of claim 53, wherein the cancer is melanoma, multiple myeloma, or a leukemia.
- 57. (Original) A method of treating cancer in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1 and another chemotherapeutic agent.
- 58. (Original) The method of claim 57, wherein the other cancer chemotherapeutic agent is paclitaxel, cisplatin, tamoxifen, docetaxel, epirubicin, doxorubicin, irinotecan, leuprolide, bicalutamide, goserelin implant, gemcitabine, or sargramostim.
- 59. (Original) The method of claim 57, wherein the other cancer chemotherapeutic agent is an anti-cancer vaccine.
- 60. (Original) A method of treating an inflammatory disorder in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1.

9516-048-999 -28 - 1972 -1415999.1

- The method of claim 60, wherein the inflammatory disorder is б1. (Original) arthritis, rheumatoid spondylitis, psoriasis, inflammatory bowel disease, post ischemic perfusion injury, or chronic inflammatory pulmonary disease.
- The method of claim 61, wherein the arthritis is rheumatoid 62. (Original) arthritis or osteoarthritis.
- A method of treating heart disease in a mammal comprising (Original) 63. administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1.
- 64. A method of modulating the production of TNF-a in a (Original) mammalian cell or tissue comprising contacting an effective amount of a compound of claim 1.
- A method of modulating the production of IL-1 β in a 65. (Original) mammalian cell or tissue comprising contacting an effective amount of a compound of claim 1.
- 66. A method of modulating the production of IL-10 in a (Original) mammalian cell or tissue comprising contacting an effective amount of a compound of claim 1.
- A method of modulating the production of T-cells in a 67. (Original) mammalian cell or tissue comprising contacting an effective amount of a compound of claim 1.
- 68. (New) A method of modulating the production of cytokines in a mammal comprising administering to said mammal an effective amount of a compound of the formula:

9516-048-999

-29 -

or a pharmacentically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof, wherein:

one of X and Y is C=O and the other is CH2 or C=O;

 $R^{1} \text{ is H, } (C_{1}-C_{8}) \text{alkyl, } (C_{3}-C_{7}) \text{cycloalkyl, } (C_{2}-C_{8}) \text{alkenyl, } (C_{2}-C_{8}) \text{alkynyl, benzyl, aryl, } (C_{0}-C_{4}) \text{alkyl-} (C_{1}-C_{6}) \text{heterocycloalkyl, } (C_{0}-C_{4}) \text{alkyl-} (C_{2}-C_{5}) \text{heteroaryl, } C(O)R^{3}, C(S)R^{3}, C(O)OR^{4}, (C_{1}-C_{8}) \text{alkyl-} N(R^{6})_{2}, (C_{1}-C_{8}) \text{alkyl-} OR^{5}, (C_{1}-C_{8}) \text{alkyl-} C(O)OR^{5}, C(O)NHR^{3}, C(O)NR^{3}R^{3}, C(S)NR^{3}R^{3}, C(C_{1}-C_{8}) \text{alkyl-} O(CO)R^{5};$

R² is H, F, benzyl, (C₁-C₈)alkyl, (C₂-C₄)alkenyl, or (C₂-C₈)alkynyl;

 R^3 and R^3 are independently (C₁-C₈)alkyl, (C₂-C₇)cycloalkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, benzyl, aryl, (C₀-C₄)alkyl-(C₁-C₆)heterocycloalkyl, (C₀-C₄)alkyl-(C₂-C₅)heteroaryl, (C₀-C₈)alkyl-N(R^6)₂, (C₁-C₈)alkyl-O R^5 , (C₁-C₈)alkyl-O(CO) R^5 , or C(O)O R^5 ;

 $R^4 \text{ is } (C_1-C_8) \text{alkyl, } (C_2-C_8) \text{alkenyl, } (C_2-C_8) \text{alkynyl, } (C_1-C_4) \text{alkyl-OR}^5, \text{ benzyl, aryl, } (C_0-C_4) \text{alkyl-(C_1-C_6)} \text{heterocycloalkyl, or } (C_0-C_4) \text{alkyl-(C_2-C_5)} \text{heterocryl;}$

 \mathbb{R}^5 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl;

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-R^5$ or the R^6 groups can join to form a heterocycloalkyl group;

n is 0 or 1; and the * represents a chiral-carbon center; with the proviso that when n is 0 then R^1 is not H.

- 69. (New) The method of claim 68 wherein the cytokine is IL-2.
- 70. (New) The method of claim 68 wherein the cytokine is interferon-y.

NY2 -1415999.1

9516-048-999

-30 -